Name | sb-435495 |
---|---|
Synonyms |
sb-435495
N-[2-(Diethylamino)ethyl]-2-{2-[(4-fluorobenzyl)sulfanyl]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-1(4H)-pyrimidinyl}-N-{[4'-(trifluoromethyl)-4-biphenylyl]methyl}acetamide 1(4H)-Pyrimidineacetamide, N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- |
Description | SB-435495 is a potent, orally active inhibitor of Lp-PLA2 with IC50 of 0.06 nM; inhibits the enzyme in whole human plasma with IC50 of 3 nM; shows little interaction with other CYP450 enzymes (CYP450 IC50: 1A2>100 mM, 2C9>100 uM, 2C19>40 uM, 2D6=37 uM); effectively suppresses BRB breakdown in streptozotocin-diabetic Brown Norway rats,. Atherosclerosis Phase 2 Discontinued |
---|---|
References | References 1. Blackie JA, et al. Bioorg Med Chem Lett. 2002 Sep 16;12(18):2603-6. 2. Canning P, et al. Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7213-8. 3. Tyurin VA, et al. Cell Death Differ. 2014 May;21(5):825-35. 4. Jiang Z, et al. Respir Res. 2012 Nov 12;13:100. View Related Products by Target Phospholipase Atherosclerosis |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 793.9±70.0 °C at 760 mmHg |
Molecular Formula | C38H40F4N6O2S |
Molecular Weight | 720.822 |
Flash Point | 433.9±35.7 °C |
Exact Mass | 720.286987 |
LogP | 7.48 |
Vapour Pressure | 0.0±2.8 mmHg at 25°C |
Index of Refraction | 1.595 |